RESMED INC — Earnings Release 2004

Sep 7, 2004

RESMED NAMED TO FORTUNE'S 2004 LIST OF AMERICA'S FASTEST GROWING COMPANIES

Sydney, Australia, September 8, 2004 - ResMed Inc. (NYSE: RMD) announced today that it has been named to FORTUNE's annual list of America's Fastest Growing Companies based on annual growth in sales and earnings over the past three years and total stock market return. The complete list and state-by-state database of the companies appeared in the September 6, 2004. issue of FORTUNE Magazine. In June of this year, ResMed marked its 37th consecutive quarter of growth. The company grew its sales by 24 percent over the prior year to reach $339.3 million in revenues for the fiscal year ended June 30, 2004. Net income for the year rose 25 percent to $57.3 million and earnings per fully diluted share were $1.63, a 23 percent increase over the prior year. Operating income was $85.4 million, an increase of 27 percent over the prior year, and shareholders' equity increased 26 percent to $361.5 million.

"As pleased as I am with the results we have achieved so far, I believe we are just starting on the journey," stated Peter C. Farrell, PhD, Chairman and Chief Executive Officer. "ResMed has been a consistent pioneer in the sleep business, from its entry into the market in 1989, and we continue to innovate. We are committed to waking people up to sleep and to improving patients' lives, by leading the industry in both clinical education and product development. Until we have succeeded in educating physicians and the public about the importance of healthy sleep, ignorance will remain our biggest competitor in this industry."

About ResMed

ResMed is a leading manufacturer of medical equipment for the diagnosis, treatment, and management of sleep-disordered breathing (SDB), which is estimated to affect approximately 43 million Americans. We are dedicated to improving awareness among patients and healthcare professionals of the potentially serious health consequences of untreated SDB and to developing innovative technology to improve the lives of those who suffer from this condition. For more information on ResMed, visit www.resmed.com.

Forward-Looking Statements

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development, and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the US Securities & Exchange Commission. Those reports are available on the Company's Web site.

Contact:

Hillary Theakston Director of Investor Relations Tel. +1 (858) 746-2610 Email hillaryt@resmed.com